↓ Skip to main content

Exosome removal as a therapeutic adjuvant in cancer

Overview of attention for article published in Journal of Translational Medicine, June 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
2 X users
patent
2 patents
facebook
1 Facebook page

Citations

dimensions_citation
343 Dimensions

Readers on

mendeley
409 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Exosome removal as a therapeutic adjuvant in cancer
Published in
Journal of Translational Medicine, June 2012
DOI 10.1186/1479-5876-10-134
Pubmed ID
Authors

Annette M Marleau, Chien-Shing Chen, James A Joyce, Richard H Tullis

Abstract

Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth, immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30-100 nm membrane vesicles released by many cells types during normal physiological processes. Tumors aberrantly secrete large quantities of exosomes that transport oncoproteins and immune suppressive molecules to support tumor growth and metastasis. The role of exosomes in intercellular signaling is exemplified by human epidermal growth factor receptor type 2 (HER2) over-expressing breast cancer, where exosomes with the HER2 oncoprotein stimulate tumor growth and interfere with the activity of the therapeutic antibody Herceptin®. Since numerous observations from experimental model systems point toward an important clinical impact of exosomes in cancer, several pharmacological strategies have been proposed for targeting their malignant activities. We also propose a novel device strategy involving extracorporeal hemofiltration of exosomes from the entire circulatory system using an affinity plasmapheresis platform known as the Aethlon ADAPT™ (adaptive dialysis-like affinity platform technology) system, which would overcome the risks of toxicity and drug interactions posed by pharmacological approaches. This technology allows affinity agents, including exosome-binding lectins and antibodies, to be immobilized in the outer-capillary space of plasma filtration membranes that integrate into existing kidney dialysis systems. Device therapies that evolve from this platform allow rapid extracorporeal capture and selective retention of target particles < 200 nm from the entire circulatory system. This strategy is supported by clinical experience in hepatitis C virus-infected patients using an ADAPT™ device, the Hemopurifier®, to reduce the systemic load of virions having similar sizes and glycosylated surfaces as cancer exosomes. This review discusses the possible therapeutic approaches for targeting immune suppressive exosomes in cancer patients, and the anticipated significance of these strategies for reversing immune dysfunction and improving responses to standard of care treatments.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 409 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 2 <1%
United States 2 <1%
Netherlands 1 <1%
Turkey 1 <1%
Hungary 1 <1%
Korea, Republic of 1 <1%
Ireland 1 <1%
Italy 1 <1%
France 1 <1%
Other 4 <1%
Unknown 394 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 86 21%
Researcher 78 19%
Student > Master 53 13%
Student > Bachelor 43 11%
Student > Doctoral Student 22 5%
Other 55 13%
Unknown 72 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 97 24%
Agricultural and Biological Sciences 92 22%
Medicine and Dentistry 67 16%
Pharmacology, Toxicology and Pharmaceutical Science 12 3%
Engineering 12 3%
Other 43 11%
Unknown 86 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2022.
All research outputs
#6,417,749
of 23,221,875 outputs
Outputs from Journal of Translational Medicine
#978
of 4,087 outputs
Outputs of similar age
#44,555
of 165,321 outputs
Outputs of similar age from Journal of Translational Medicine
#16
of 67 outputs
Altmetric has tracked 23,221,875 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 4,087 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,321 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.